05th week of 2013 patent applcation highlights part 39 |
Patent application number | Title | Published |
20130028816 | SELECTIVE BASE METALS LEACHING FROM LATERITE ORES - A process to use ferric sulphate equilibrium to reduce overall acid consumption and iron extraction, the process comprising the steps of: (i) sulphating; (ii) selective pyrolysis and (iii) selective dissolution. | 2013-01-31 |
20130028817 | DIESEL EXHAUST FLUID FORMULATION HAVING A HIGH AMMONIUM CONTENT AND A LOW FREEZING POINT - A mixture of urea, water and ammonium carbamate is formulated for use in the catalytic reduction of oxides of nitrogen in diesel exhaust. The mixtures may be formulated to optimize the amount of reductant in the mixture and the freezing point of the formulation. These formulations are especially useful in combination with Selective Catalytic Reduction systems and are well suited for use on heavy-duty trucks and heavy duty equipment used off-road. Some of these formations include between about 15.0 wt. % to about 40.0 wt. % urea; between about 15.0 wt. % to about 40.0 wt. % ammonium carbamate; and between about 40.0 wt. % to about 60.0 wt. % water. The formulation may be monitored for ammonia content and/or freezing point and the composition of the formulation may be adjusted to optimize the freezing point and ammonia content. | 2013-01-31 |
20130028818 | METHOD OF DEPLETING NITROUS OXIDE IN EXHAUST GAS AFTER-TREATMENT FOR LEAN-BURN ENGINES - The present invention relates to a method for exhaust gas after-treatment for essentially lean-burn internal combustion engines and also a corresponding advantageous exhaust gas after-treatment system. In particular, the present invention relates to reducing the proportion of the greenhouse gas N20 in the total exhaust gas from a corresponding internal combustion system using at least one NOx storage catalyst as exhaust gas purification element. The objective of the invention is to operate the N20 depletion catalyst located downstream of the NOx storage catalyst under lambda=<1 conditions when the N20 formed by the NOx storage catalyst reaches the N20 depletion catalyst. | 2013-01-31 |
20130028819 | CATALYTIC CONVERTER APPARATUS - A catalytic converter apparatus for use in an exhaust system of an internal combustion engine includes a housing having a gas inlet and a gas outlet, and at least one catalytic substrate element disposed in the housing. The at least one substrate element is divided into a plurality of zones or sections, the zones at least partially separated from one another to inhibit heat flow. The zones can be at least partially separated with walls. The walls can include insulating material for reducing the mobility of heat radially outwardly. Each of the zones defines a generally separate flow passage connecting the inlet and outlet in fluid communication. The apparatus can heat more rapidly from a cold start compared with conventional catalytic converters. | 2013-01-31 |
20130028820 | Exhaust Gas Treating Apparatus and Treating Method for Carbon Dioxide Capture Process - Disclosed are an exhaust gas treating apparatus and a treating method for a carbon dioxide capture process, in which harmful substances remaining in the exhaust gas discharged from the conventional flue-gas desulfurization process are additionally removed for efficient performance of the carbon dioxide capture process. According to the exhaust gas treating apparatus for a carbon dioxide capture process, it has the effects of minimizing the installation space of desulfurization equipment and reducing the process cost. In addition, by keeping the contaminants contained in the gas introduced in the carbon dioxide capture equipment below a proper level, absorption performance can be improved as degradation of the absorbent used in the carbon dioxide capture process is prevented. After all, it has an advantage of preventing the pollution by the exhaust gas discharged into the atmosphere. | 2013-01-31 |
20130028821 | PROCESS FOR REMOVING CONTAMINANTS FROM GAS STREAMS - The present invention provides for process for inhibiting the levels of nitrogen oxides in process gas streams from sulfuric acid regeneration and sulfuric acid production plants. Partial oxidation of the nitrogen oxides is achieved by feeding a sub stoichiometric amount of ozone as to nitrogen oxides to the process gas stream. | 2013-01-31 |
20130028822 | CATALYTIC COMPOSITIONS USEFUL IN REMOVAL OF SULFUR COMPOUNDS FROM GASEOUS HYDROCARBONS, PROCESSES FOR MAKING THESE AND USES THEREOF - A catalytic composition is disclosed, which exhibits an X-ray amorphous oxide, with a spinel formula and highly dispersed crystals of ZnO, CuO, and optionally CeO | 2013-01-31 |
20130028823 | DOPED, PASSIVATED GRAPHENE NANOMESH, METHOD OF MAKING THE DOPED, PASSIVATED GRAPHENE NANOMESH, AND SEMICONDUCTOR DEVICE INCLUDING THE DOPED, PASSIVATED GRAPHENE NANOMESH - A method of making a semiconductor device, includes providing a graphene sheet, creating a plurality of nanoholes in the graphene sheet to form a graphene nanomesh, the graphene nanomesh including a plurality of carbon atoms which are formed adjacent to the plurality of nanoholes, passivating a dangling bond on the plurality of carbon atoms by bonding a passivating element to the plurality of carbon atoms, and doping the passivated graphene nanomesh by bonding a dopant to the passivating element. | 2013-01-31 |
20130028824 | PREPARATION METHOD OF ZINC MANGANESE SILICATE - A preparation method of zinc manganese silicate is provided. The method includes the following steps: step | 2013-01-31 |
20130028825 | MANUFACTURING METHOD FOR POLYCRYSTALLINE SILICON INGOT, AND POLYCRYSTALLINE SILICON INGOT - A method for manufacturing a polycrystalline silicon ingot includes: solidifying a silicon melt retained in a crucible unidirectionally upward from a bottom surface of the silicon melt, wherein a silicon nitride coating layer is formed on inner surfaces of side walls and an inner side surface of a bottom of the crucible, a solidification process in the crucible is divided into a first region from 0 mm to X (10 mm≦X<30 mm) in hight, a second region from X to Y (30 mm≦Y<100 mm), and a third region of the Y or higher, with the bottom of the crucible as a datum, a solidification rate V1 in the first region is in a range of 10 mm/h≦V1≦20 mm/h, and a solidification rate V2 in the second region is in a range of 1 mm/h≦V2≦5 mm/h. | 2013-01-31 |
20130028826 | GROUP III NITRIDE CRYSTAL AND MANUFACTURING METHOD THEREOF - A group III nitride crystal containing therein an alkali metal element comprises a base body, a first group III nitride crystal formed such that at least a part thereof makes a contact with the base body, the first group III nitride crystal deflecting threading dislocations in a direction different from a direction of crystal growth from the base body and a second nitride crystal formed adjacent to the first group III nitride crystal, the second nitride crystal having a crystal growth surface generally perpendicular to the direction of the crystal growth. | 2013-01-31 |
20130028827 | AMMONIUM RECOVERY FROM WASTE WATER USING CO2 ACIDIFIED ABSORPTION WATER - The processes are utilized to recover ammonium from waste water using CO | 2013-01-31 |
20130028828 | Conversion of gaseous carbon dioxide into aqueous alkaline and/or alkaline earth bicarbonate solutions - A material with cationic exchanger properties is introduced into aqueous media, where the equilibriums of carbon dioxide dissolution take place. A cationic exchanger material x/nM | 2013-01-31 |
20130028829 | SYSTEM AND METHOD FOR GROWTH OF ENHANCED ADHESION CARBON NANOTUBES ON SUBSTRATES - Disclosed herein is a method of growth of enhanced adhesion MWCNTs on a substrate, referred to as the HGTiE process, the method comprising: chemical vapor deposition of an adhesive underlayer composed of alumina on a substrate composed of titanium or similar; chemical vapor deposition of a catalyst such as a thin film of iron on top of the adhesive underlayer; pretreatment of the substrate to hydrogen at high temperature; and exposure of the substrate to a feedstock gas such as ethylene at high temperature. The substrate surface may be roughened before placement of an adhesive layer through mechanical grinding or chemical etching. Finally, plasma etching of the MWCNT film may be performed with oxygen plasma. This method of growth allows for high strength adhesion of MWCNTs to the substrate the MWCNTs are grown upon. | 2013-01-31 |
20130028830 | ENHANCEMENT OF THE STRUCTURE AND PROPERTIES OF CARBON NANOTUBE FIBRES AND FILMS - A method of increasing the density of carbon nanotube fibres or films containing carbon nanotubes to at least 50% w/w, said method including the steps of exposing the fibre or film to suitable density enhancing agent. | 2013-01-31 |
20130028831 | POROUS CARBON PRODUCT AND METHOD FOR PRODUCING AN ELECTRODE FOR A RECHARGEABLE LITHIUM BATTERY - A known method for producing a porous carbon body comprises providing a template of inorganic template material which comprises interconnected pores, providing a precursor substance for carbon, infiltrating the pores of the template with the precursor substance, carbonizing the precursor substance and removing the template with formation of the porous carbon product. Starting therefrom, to provide a method which allows a cost-effective production of a porous carbon structure also with thick wall thicknesses, it is suggested according to the invention that precursor substance particles of fusible material and template particles are provided and a powder mixture is formed from the particles, and that the powder mixture is heated before or during carbonization according to method step (d) in such a manner that precursor substance melt penetrates into the pores of the template particles. | 2013-01-31 |
20130028832 | METHODS FOR THE SEPARATION OF HCL FROM A CARBOHYDRATE AND COMPOSITIONS PRODUCED THEREBY - The present invention provides an organic phase composition comprising:
| 2013-01-31 |
20130028833 | METHOD FOR PREPARING A HYDROLYZATE - The present invention provides an organic phase composition comprising
| 2013-01-31 |
20130028834 | PROCESS FOR THE GASIFICATION OF HEAVY RESIDUAL OIL WITH PARTICULATE COKE FROM A DELAYED COKING UNIT - A process for the production of a synthesis gas containing hydrogen and carbon monoxide utilizes ground coke having a predetermined ash content in combination with a refinery residual hydrocarbon oil feedstream for gasification in the combustion chamber of a tubular wall membrane partial oxidation gasification reactor in the presence of a predetermined amount of oxygen; the coke and residual oil can be mixed to form a single feedstream or introduced into the reactor as separate feeds. Optionally, the product synthesis gas is introduced as the feedstream to a water-gas shift reactor to enhance the hydrogen content of the final product stream. | 2013-01-31 |
20130028835 | METHOD FOR GENERATING ACTIVE ANTIBODIES AGAINST A RESISTANCE ANTIGEN, ANTIBODIES OBTAINED BY SAID METHOD AND THEIR USES - The present invention relates to the use of a milled homogenate and/or a suspension and/or a cell lysate, stemming from a tumor resistant to at least one anti-tumoral compound in order to immunize and generate in vitro an antibody, or one of its functional fragments, directed against a tumoral antigen specifically expressed at the surface of said resistant tumor and being possibly involved in the resistance of said resistant tumor. More particularly, the present invention is directed to such antibodies obtained by applying the method, such as the antibodies 1A6, 1A9, 2E11, 3C11 and 3G7, as well as to their use for treating cancer. | 2013-01-31 |
20130028836 | CHLOROTOXIN POLYPEPTIDES AND CONJUGATES AND USES THEREOF - Reduced lysine chlorotoxin polypeptides that may be used to generate single species conjugates of chlorotoxin. Conjugates comprising such chlorotoxin polypeptides and pharmaceutical compositions thereof. Methods of using such compositions and/or conjugates. | 2013-01-31 |
20130028837 | CONTRAST AGENTS FOR MYOCARDIAL PERFUSION IMAGING - The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging. | 2013-01-31 |
20130028838 | F18-TYROSINE DERIVATIVES FOR IMAGING BONE METASTASES - This invention relates to radioactive tyrosine derivatives for imaging bone metastases, a method for imaging or diagnosing bone metastases, compositions and kits for imaging bone metastases. | 2013-01-31 |
20130028839 | POLYMER COATED SERS NANOTAG - An encapsulated surface enhanced Raman scattering (SERS) tag. The tag includes a metal core and an encapsulant, typically a glass encapsulant. The encapsulant is further derivatized with a polymer. | 2013-01-31 |
20130028840 | FABRICATION OF CONDUCTING OPEN NANOSHELLS - A method involving ion milling is demonstrated to fabricate open-nanoshell suspensions and open-nanoshell monolayer structures. Ion milling technology allows the open-nanoshell geometry and upward orientation on substrates to be controlled. Substrates can be fabricated covered with stable and dense open-nanoshell monolayer structures, showing nanoaperture and nanotip geometry with upward orientation, that can be used as substrates for SERS-based biomolecule detection. | 2013-01-31 |
20130028841 | MIXING DEVICE, MIXING TUBE, DRUG SOLUTION INJECTING SYSTEM, AND DRUG SOLUTION MIXING METHOD - To provide a mixing device, a mixing tube, a drug solution injecting system, and a drug solution mixing method capable of evenly and efficiently mixing a plurality of kinds of drug solutions. The mixing device according to the present invention includes: a swirling flow generating chamber; a first inflow opening for introducing a first drug solution into the swirling flow generating chamber in a direction parallel to a central axis of the swirling flow; a second inflow opening for introducing a second drug solution into the swirling flow generating chamber so as to generate a swirling flow of the second drug solution having a specific gravity lower than that of the first drug solution; an outflow opening for discharging a mixed drug solution; and a narrowing chamber which is interposed between the swirling flow generating chamber and the outflow opening and has a space continuously narrowed toward the outflow opening. | 2013-01-31 |
20130028842 | METHOD OF TREATING BINGE EATING DISORDER - The invention provides methods of treating binge eating disorders, obesity resulting from binge eating behavior, and depression. The invention includes methods of treating certain co-morbidities in ADHD and ADD patients; for example the invention includes methods of treating generalized anxiety disorder, obsessional and ruminative thought disorders, and obsessive/compulsive behavior in ADHD and ADD patients. The invention also includes combination methods of treatment in which an amphetamine prodrug, methylphenidate prodrug, or methylphenidate analog is administered with one or more other active agents. Packaged pharmaceutical compositions containing an amphetamine or methylphenidate prodrug, instructions for using the pro drug to treat certain disorders, and optionally one or more other active agents are provided by the invention. | 2013-01-31 |
20130028843 | KALLIKREIN 7 MODULATORS - The present invention relates to the crystal structure of the serine protease kallikrein 7 and to the use of this crystal structure in drug discovery. The present invention also relates to compounds binding specifically to this active site of kallikrein 7. | 2013-01-31 |
20130028844 | PREPARATIONS FOR EFFERVESCENT FORMULATIONS COMPRISING CEPHALOSPORIN AND USES THEREOF - The present invention relates to a process for preparing effervescent dosage forms comprising at least one antibiotic of cephalosporin group. The present invention also relates to effervescent formulations and preparations comprising antibiotics of second generation cephalosporin. | 2013-01-31 |
20130028845 | LEVALBUTEROL SALT - Levalbuterol L-tartrate affords crystals possessing properties desirable for use in a metered dose inhaler. | 2013-01-31 |
20130028846 | Flavour Modulating Derivative of a Carboxylic Acid and a Purine, Pyrimidine, Nucleoside, or Nucleotide - The present invention relates to the field of improving the flavour of foodstuffs, beverages, tobacco products, pharmaceutics and oral care products. More particularly, the present invention provides flavour modulating substances selected from the group represented by formula (I): | 2013-01-31 |
20130028847 | BIOFILM TREATMENT - The invention provides a method of preventing, inhibiting or reducing a | 2013-01-31 |
20130028848 | METHOD OF INHIBITING HARMFUL MICROORGANISMS AND BARRIER-FORMING COMPOSITION THEREFOR - A method for blocking, neutralizing, or killing microorganisms that cause infectious disease in a mammal prior to or during the mammal encountering a contaminated environment or item includes: identifying a contaminated environment or item, wherein the contaminated environment or item is known or expected to be contaminated with harmful viral, fungal, or bacterial microorganisms; and administering a therapeutically effective amount of a barrier-forming composition to a mucosa of the mammal prior to or during the mammal encountering the contaminated environment or item. The barrier-forming composition provides a barrier on the mucosa that inhibits the microorganisms from contacting the mucosa. Other related methods are also included. | 2013-01-31 |
20130028849 | Agent For Stimulating The Expression of Loxl - The present invention concerns a novel agent which is capable of stimulating the expression of LOXL and of increasing quality and functionality of collagen fibres and has anti-oxidizing, anti-elastase, anti-MMP properties as well as its use in producing cosmetic or pharmaceutical compositions, especially dermatological compositions, or food compositions. | 2013-01-31 |
20130028850 | TOPICAL TETRACYCLINE COMPOSITIONS - A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents; and the amount of viscosity modifying agents can optionally be reduced by at least an amount by weight that would have increased the viscosity of the carrier without the tetracycline antibiotic by at least 30%; wherein the tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down; wherein when packaged in an aerosol container to which is added a liquefied or compressed gas propellant the composition affords upon release from the container a breakable foam of at least good quality that breaks easily upon application of shear force. | 2013-01-31 |
20130028851 | SUNSCREEN COMPOSITION WITH IMPROVED AESTHETIC PROPERTIES - Compositions for the protection of an object from UV light are provided. For example, in certain aspects, the compositions can include a plurality of silicone-containing compounds that improve the aesthetic properties. | 2013-01-31 |
20130028852 | OIL-IN-WATER EMULSION COMPOSITION - A oil-in-water emulsion composition which contains a low solubility but oil-soluble ultraviolet absorber. and which exhibits superior stability. The composition contains (a) an aqueous dispersion of an oil-soluble ultraviolet absorber; (b) a compound of a non-ionic surfactant and at least one type of fatty acid soap; (c) a water-swelling clay mineral: and (d) a higher fatty acid. Component (a) is preferably an aqueous dispersion of a complex particle of an oil-soluble ultraviolet absorber and an organic polymer. | 2013-01-31 |
20130028853 | HIGH SPF SUNSCREEN COMPOSITIONS - Methods and composition for the protection of an object from UV light are provided. For example, in certain aspects, the composition can include a plurality of photo stabilizers that enhance SPF values of the composition. Furthermore, the invention provides for the use of the compositions. | 2013-01-31 |
20130028854 | Osmoprotective Complexes for Prevention of Mitochondrial Free Radical Damage Related Skin Aging - The present invention discloses a method to inhibit a free radical, including a mitochondrial free radical, comprising administering to a subject in need thereof an effective amount of a composition comprising a compound of formula (I: a, b), an isomer, or a salt thereof: | 2013-01-31 |
20130028855 | SOFT SOLID ANTIPERSPIRANT COMPOSITIONS INCLUDING STEARYL ALCOHOL AND CETYL AND/OR MYRISTYL ALCOHOL - Soft solid antiperspirant compositions are provided. In accordance with an exemplary embodiment, an antiperspirant composition comprises an active antiperspirant compound, a first fatty alcohol constituent comprising stearyl alcohol, and a second fatty alcohol constituent comprising C | 2013-01-31 |
20130028856 | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions - Provided are combinations, compositions and kits containing a hyaluronan degrading enzyme, such as a soluble hyaluronidase, for treatment of hyaluronan-associated conditions, diseases and disorders. In one example, the products include an additional agent or treatment. Such products can be used in methods for administering the products to treat the hyaluronan-associated diseases and conditions, for example, hyaluronan-associated cancers, for example, hyaluronan-rich tumors. The methods include administration of the hyaluronan degrading enzyme composition alone or in combination with other treatments. Also provided are methods and compositions for providing sustained treatment effects in hyaluronan-associated diseases and conditions. | 2013-01-31 |
20130028857 | SYNTHETIC NANOCARRIERS COMPRISING POLYMERS COMPRISING MULTIPLE IMMUNOMODULATORY AGENTS - This invention relates to compositions, and related methods, of synthetic nanocarriers that comprise polymers that comprise at least two immunomodulatory agent moieties. | 2013-01-31 |
20130028858 | COMPOSITION AND METHOD FOR ATTRACTION OF EMERALD ASH BORER AGRILUS PLANIPENNIS FAIRMAIRE (COLEOPTERA: BUPRESTIDAE) - The invention disclosed relates to a novel composition and use thereof, for the attraction and detection of emerald ash borer, | 2013-01-31 |
20130028859 | Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 2013-01-31 |
20130028860 | ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE AND/OR FEVER - The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved. | 2013-01-31 |
20130028862 | TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. | 2013-01-31 |
20130028863 | PROMYELOCYTIC LEUKEMIA PROTEIN AS A REDOX SENSOR - The present invention relates to a method for determining the redox status of a cell or tissue comprising a step consisting of determining the level of PML nuclear bodies in said cell or tissue. | 2013-01-31 |
20130028864 | ANTI-INFLAMMATORY COMPOSITIONS FOR TREATING BRAIN INFLAMMATION - Compositions with synergistic anti-inflammatory effects in inflammatory diseases resulting from activation and consequent degranulation of mast cells and followed by secretion of inflammatory biochemicals from the activated mast cells, the compositions containing one or more of a flavone or flavonoid glycoside a heavily sulfated, non-bovine proteoglycan, an unrefined olive kernel extract that increases absorption of these compositions in various routes of administration, a hexosamine sulfate such as D-glucosamine sulfate, S-adenosylmethionine, a histamine-1 receptor antagonist, a histamine-3 receptor agonist, an antagonist of the actions of CRR, a long-chain unsaturated fatty acid, a phospholipid, Krill oil, a polyamine, glutiramer acetate and interferon. Certain of the present compositions are useful in protecting against the neuropathological components of multiple sclerosis and similar inflammatory neurological diseases. | 2013-01-31 |
20130028865 | Combination of a Macrocyclic Inhibitor of HCV, A Non-Nucleoside and a Nucleoside - The present invention relates to a combination of a macrocyclic HCV protease inhibitor, a macrocyclic non-nucleoside HCV polymerase inhibitor and a nucleoside HCV polymerase inhibitor. | 2013-01-31 |
20130028866 | TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND INTERFERON-BETA - This invention provides a method of treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the patient laquinimod as an add-on therapy to or in combination with interferon-β. This invention also provides a package and a pharmaceutical composition comprising laquinimod and interferon-β for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with interferon-β in treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and interferon-β in the preparation of a combination for treating a patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome. | 2013-01-31 |
20130028867 | LONG-ACTING INTERFERON BETA FORMULATION USING IMMUNOGLOBULIN FRAGMENT - The present invention relates to a long-acting interferon beta formulation having improved in vivo duration and stability, comprising an interferon beta conjugate that is prepared by covalently linking interferon beta with an immunoglobulin Fc region via a non-peptidyl polymer, and a preparation method thereof. The long-acting interferon beta formulation of the present invention maintains in vivo activity of interferon beta at a relatively high level and remarkably increases the serum half-life thereof, thereby being used for various diseases, for which interferon is efficacious. | 2013-01-31 |
20130028868 | CLINICAL APPLICATIONS OF A RECOMBINANT HUMAN ENDOSTATIN ADENOVIRUS (E10A) INJECTION - The present invention relates to the genetic engineering field of angiogenesis-targeted therapy. Particularly, a recombinant human endostatin adenovirus injection is used along with certain antitumor agents for treating specific tumors. The methods of the invention offer significant improvement of effective response rate, disease control rate, survival and quality of life. The injection and treatment has no significant adverse reactions and side effects. | 2013-01-31 |
20130028869 | FEED SUPPLEMENT COMPRISING OLIGOSACCHARIDES AND MEDIUM CHAIN FATTY ACIDS - The present invention relates to a feed supplement and a feed containing this feed supplement, comprising 1) a homotrimer, heterotrimer, homotetramer and/or heterotetramer of a carbohydrate component selected from the group consisting of a pentose saccharide, a hexose saccharide, glucuronic and galacturonic acid, and 2) a medium-chain fatty acid (MCFA), selected from the group consisting of caproic acid (C6), caprylic (C8), capric (C10) and lauric acid (C12). The invention also refers to the use of the feed supplement or feed in order to improve the efficiency of animal production, such as weight gain, feed conversion, nutritive value, health and wellbeing through the selective elimination of enteropathogens. | 2013-01-31 |
20130028870 | PLURIPOTENT STEM CELLS AND METHOD OF STIMULATING AND EXTRACTING NON-EMBRYONIC PLURIPOTENT STEM CELLS FROM MAMMAL BLOOD AND USING RECONSTITUTED PLURIPOTENT STEM CELLS TO TREAT DISEASES INCLUDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE - Stimulating tissue resident pluripotent stem cells in a manner that the respective subject (e.g., human) acts as its own sterile bioreactor for in vivo stem cell proliferation thus eliminating the need to isolate, cultivate, maintain, proliferate and release stem cells ex vivo. The stimulation mobilizes excess pluripotent stem cells into the peripheral vasculature where the pluripotent stem cells can either migrate to damaged tissues and/or be harvested by simple venipuncture, thus eliminating potential morbidity and mortality elicited from harvesting tissue from solid tissue sites. The pluripotent stem cells are separated from the blood by gravity sedimentation, after which the pluripotent stem cells can easily be aspirated from the white blood cells and red blood cells. Billions of pluripotent stem cells can be generated in this fashion for infusion/injection into the body, via the vasculature, and into the organ(s) in need of tissue repair and regeneration. | 2013-01-31 |
20130028871 | PLACENTAL STEM CELL POPULATIONS - The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting. | 2013-01-31 |
20130028872 | COMPOSITION AND METHOD FOR DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS - Described are methods for inducing differentiation of a human embryonic stem cell or a population of human embryonic stem cells toward a cell or population of cells characteristic of the definitive endoderm, the method comprising incubating the cell or population of cells with a GSK-3 inhibitor. Also described are methods for inducing differentiation of a cell or population of cells, characteristic of the definitive endoderm, towards a hepatocyte-like cell or a population of hepatocyte-like cells, and methods for inducing differentiation of a human embryonic stem cell or a population of human embryonic stem cells toward a hepatocyte-like cell or a population of hepatocyte-like cells. Further described are cells obtained by the methods and uses thereof in therapy and toxicity screening. | 2013-01-31 |
20130028873 | METHOD FOR INCREASING ACTIVITY IN HUMAN STEM CELL - Provided are a method for preparing a highly active human mesenchymal stem cell, which includes forming a spherical cell aggregate by cultivating human mesenchymal stem cells against gravity; a highly active stem cell prepared thereby; a cell therapeutic agent including the stem cell aggregate; and a method for forming a spherical cell aggregate by cultivating human mesenchymal stem cells, wherein the amount of E-cadherin in the mesenchymal stem cell is increased during the cultivation. | 2013-01-31 |
20130028874 | METHODS, PHARMACEUTICAL COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR ADMINISTERING THERAPEUTIC CELLS TO THE ANIMAL CENTRAL NERVOUS SYSTEM - Methods and compositions for preventing and treating the damaged and/or degenerating CNS experiencing loss or death of CNS cells. Various embodiments of the invention transport a therapeutically effective amount of, inter alia, at least one therapeutic cell to the CNS by intranasal application to the upper-third of the nasal cavity, thereby bypassing the blood-brain barrier. A pharmaceutical composition according to the invention may comprise at least one therapeutic cell, at least one delivery-enhancement agent, at least one antibiotic, at least one regulatory factor and/or at least one immunosuppressive agent, wherein the composition is delivered to the upper-third of the nasal cavity. The therapeutic cells, once delivered to the CNS, migrate preferentially to the area of damage or degeneration or injury. | 2013-01-31 |
20130028875 | Immune Effector Cells Pre-Infected with Oncolytic Virus - Compositions and methods are provided for the treatment of cancer. An immune effector cell population is pre-infected with an oncolytic virus. The combined therapeutic is safe and highly effective, producing an enhanced anti-tumor effect compared to either therapy alone. The methods of the invention thus provide for a synergistic effect based on the combined biotherapeutics. | 2013-01-31 |
20130028876 | THYMIDINE KINASE - A polynucleotide comprising a nucleotide sequence encoding a thymidine kinase wherein at least one of the nucleotides corresponding to the splice donor site nucleotides is replaced by another nucleotide and wherein the nucleotides of the splice acceptor sites are not altered. | 2013-01-31 |
20130028877 | LACTOBACILLUS JOHNSONII La1 NCC533 (CNCM I-1225) AND IMMUNE DISORDERS - The present invention generally relates to the field of preventing and/or treating inflammatory and infectious disorders, in particular by boosting the endogenous antimicrobial defences. One embodiment of the present invention is the use of non-replicating | 2013-01-31 |
20130028878 | S-ADENOSYL-L-METHIONINE-CONTAINING DRY YEAST COMPOSITION WITH EXCELLENT STORAGE STABILITY AND PROCESS FOR PRODUCING SAME - A dry yeast composition which includes 5-adenosyl-L-methionine and a thickener and has excellent storage stability. A thickener is added to a yeast cell concentrate obtained by culturing yeast which has SAMe-producing ability and collecting the cells, and the resultant mixture is dried. Thus, a dry yeast containing a high concentration of 5-adenosyl-L-methionine which has excellent storage stability and excellent bioabsorbability can be easily and profitably produced. It is hence possible to supply a market with a dry yeast composition that contains a high concentration of 5-adenosyl-L-methionine, which is useful as a water-soluble physiologically active substance, and that has excellent storage stability and bioabsorbability. | 2013-01-31 |
20130028879 | METHOD FOR CONTROLLING PARTICULAR INSECT PESTS BY APPLYING ANTHRANILAMIDE COMPOUNDS - This invention pertains to a method for controlling lepidopteran, homopteran, hemipteran, thysanopteran and coleopteran insect pests comprising contacting the insects or their environment with an arthropodicidally effective amount of a compound of Formula I, its N-oxide or an agriculturally suitable salt thereof. | 2013-01-31 |
20130028880 | APYRASE THERAPY FOR BLEEDING CONDITIONS - This invention provides new methods of treating subjects experiencing or at risk of bleeding due to vascular injury, especially to the microvasculature and/or platelet desensitization. Examples of injury usefully treated by apyrase agents are patho-physiological conditions, ischemia reperfusion injury, injury from pharmacologic agents such as anticoagulants, antiplatelet agents, antithrombotics, thrombolytics, and/or immunosuppressants, and injury resulting from transplantation. Apyrase agents are also useful to maintain organ function when said organs are transplanted into an allogeneic recipient. | 2013-01-31 |
20130028881 | DIAGNOSIS AND TREATMENT OF MULTIPLE SULFATASE DEFICIENCY AND OTHER SULFATASE DEFICIENCIES - This invention relates to methods and compositions for the diagnosis and treatment of Multiple Sulfatase Deficiency (MSD) as well as other sulfatase deficiencies. More specifically, the invention relates to isolated molecules that modulate post-translational modifications on sulfatases. Such modifications are essential for proper sulfatase function. | 2013-01-31 |
20130028882 | ANTIVIRAL COMPOSITIONS AND METHODS OF THEIR USE - Novel compositions comprising carrageenans well as methods of their use are disclosed. Certain novel compositions are useful, inter alia, in the prevention, inhibition and/or treatment of dengue fever (DF), dengue fever shock syndrome (DSS) or dengue hemorrhagic fever (DHF). Other compositions are useful, inter alia, for treatment of viral infections. | 2013-01-31 |
20130028883 | Treatment of ischemic episodes and cerebroprotection through Misoprostol - The present invention provides compositions and methods for treating an ischemic episode using misoprostol alone or in combination with anti-thrombotic agents. | 2013-01-31 |
20130028884 | COMPOSITION AND METHOD FOR TREATMENT OF BRUISING - There is provided a skin treatment composition for oral or topical administration and a method for skin treatment. The composition comprises a chelating agent and at least one protease. The composition helps to remove hemosiderin that causes staining of skin on a bruised area and reduces inflammation and pain. | 2013-01-31 |
20130028885 | METHODS TO PREDICT AND PREVENT RESISTANCE TO TAXOID COMPOUNDS - Embodiments of the invention are directed to methods for predicting the resistance of cancer to members of the taxoid family by measuring the levels of prohibitin. Methods for treating cancer and taxoid family member resistant cancers using inhibitors of prohibitin, as well as therapeutic complexes that target prohibitin are also provided. | 2013-01-31 |
20130028886 | PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11 (PTPN11) AND TUMOR INITIATING CELLS - The present invention relates to a method for treating cancer in a subject by killing tumor initiating cells, inducing differentiation of tumor initiating cells into differentiated cells or blocking the conversion of differentiated tumor cells into tumor initiating cells, which method comprises the step of administering to said subject a therapeutically effective amount of a modulator of the protein tyrosine phosphatase, non-receptor type 11 (PTPN11) gene or of its gene product (Shp2). The present invention also provides a siRNA decreasing or silencing the expression of protein tyrosine phosphatase, non-receptor type 11 (PTPN11) and/or an antibody specifically binding to protein tyrosine phosphatase, non-receptor type 11 (PTPN11), for use as a medicament to treat cancer according to the methods described herein. The present invention also provides a peptide comprising an amino acid sequence specifically recognized by protein tyrosine phosphatase, non-receptor type 11 (PTPN11), for use as a medicament to treat cancer according to the methods described herein above. | 2013-01-31 |
20130028887 | PHENYLACETIC ACID COMPOUND - A compound represented by formula (I), | 2013-01-31 |
20130028888 | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease - The present invention provides chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7. The anti-CD22 antibodies of the invention comprise four human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and four human or humanized framework regions of the immunoglobulin light chain variable region (“VK”). The invention further comprises heavy and/or light chain FW regions that contain one or more backmutations in which a human FW residue is exchanged for the corresponding residue present in the parental mouse heavy or light chain. Human or humanized VH framework regions of antibodies of the invention may comprise one or more of the following residues: a valine (V) at position 24 of framework region 1, a glycine (G) at position 49 of framework region 2, and an asparagine (N) at position 73 of framework region 3, numbered according to Kabat. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using therapeutic antibodies that bind to the human CD22 antigen and that preferably mediate human ADCC, CDC, and/or apoptosis for: the treatment of B cell diseases and disorders in human subjects, such as, but not limited to, B cell malignancies, for the treatment and prevention of autoimmune disease, and for the treatment and prevention of graft-versus-host disease (GVHD), humoral rejection, and post-transplantation lymphoproliferative disorder in human transplant recipients. | 2013-01-31 |
20130028889 | DOSING REGIMENS FOR TREATING AND PREVENTING OCULAR DISORDERS USING C-RAF ANTISENSE - The present invention provides methods and dosing regimens for treating and preventing ocular disorders using c-raf antisense oligonucleotides, alone or in combination with other agents. | 2013-01-31 |
20130028890 | METHOD FOR DETECTING REGULATORY T CELLS USING EXPRESSION OF FOLATE RECEPTOR 4 AS INDICATOR, METHOD FOR TREATING DISEASES USING THE DETECTION METHOD, PHARMACEUTICAL COMPOSITION FOR IMMUNOSTIMULATION, AND METHOD FOR TREATING DISEASES USING THE COMPOSITION - An object of the present invention is to provide a technique to distinguish between T | 2013-01-31 |
20130028891 | Unconjugated Anti-TfR Antibodies and Compositions Thereof for the Treatment of Cancer - Disclosed herein are methods and compositions for treating cancer. In particular, the in vivo efficacy of unconjugated anti-TfR antibodies, such as ch128.1, are disclosed herein. | 2013-01-31 |
20130028892 | METHOD OF TREATING OSTEOARTHRITIS WITH AN ANTIBODY TO NGF - Methods are disclosed for treating osteoarthritis in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of an anti-human NGF antibody, or antigen-binding fragment thereof, wherein at least one symptom associated with osteoarthritis is prevented, ameliorated or improved. | 2013-01-31 |
20130028893 | Therapeutic antibodies with reduced side effect - A therapeutic protein, such as a therapeutic antibody, that is modified with a compound that inhibits binding of the protein to its therapeutic target, thereby reducing side effects caused by the protein. | 2013-01-31 |
20130028894 | METHODS OF TREATING IL-TIF ASSOCIATED INFLAMMATORY OR IMMUNE DISEASES USING ANTIBODIES AGAINST SOLUBLE ZCYTOR 11 CYTOKINE RECEPTORS - Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for soluble zcytor11 receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides and antibodies can also be used to block TIF activity in vitro and in vivo, and may be used in conjunction with TIF and other cytokines to selectively stimulate the immune system. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. | 2013-01-31 |
20130028895 | EXOSOME INHIBITING AGENTS AND USES THEREOF - The invention relates to methods and compositions for reducing exosome mediated tumor resistance against a therapeutic binding molecule and for increasing the efficacy of a therapeutic binding molecule suitable in the treatment of a disease. The methods include administering an effective amount of at least one agent inhibiting exosome formation and administering the therapeutic binding molecule. | 2013-01-31 |
20130028896 | Semaphorin 3C (Sema3C) Inhibitor Therapeutics, Methods, and Uses - Provided are methods, uses and pharmaceutical compositions for treatment of prostate cancer with a SEMA3C inhibitor in a biologically effective amount sufficient to cause cell death of a prostate cancer cell or to inhibit proliferation of the prostate cancer cells. The prostate cancer may be an androgen receptor (AR) positive prostate cancer and the SEMA3C inhibitor may be selected from one or more of the following: an antibody, a SEMA3C peptide, an antisense RNA, a siRNA, a shRNA or a small molecule. | 2013-01-31 |
20130028897 | METHODS FOR REDUCING THE LEVEL OF ALLOANTIBODIES IN A SUBJECT - The invention provides a method for reducing the level of alloantibodies in a sensitized patient awaiting kidney transplantation by administering Belimumab or an antibody that specifically binds a B-lymphocyte stimulator protein (BLyS). The invention further provides a method for reducing the risk of an allograft rejection in an allograft recipient by administering Belimumab or an antibody that specifically binds a BLyS. | 2013-01-31 |
20130028898 | COMBINATION THERAPY WITH CD4 LYMPHOCYTE DEPLETION AND MTOR INHIBITORS - The invention provides methods for treating a malignant neoplastic cell proliferative disorder or disease, comprising administering to a subject in need thereof an effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent. Such methods find utility in the treatment of certain subsets of malignant neoplastic cell proliferative disorders or diseases, e.g. renal cell carcinoma and melanoma. The invention also provides for pharmaceutical compositions comprising a therapeutically effective amount of an mTOR inhibitor and an effective amount of a CD4 lymphocyte depleting agent in a pharmaceutically acceptable carrier. | 2013-01-31 |
20130028899 | TREATMENT OF CANCER BY INHIBITING ACTIVITY OR EXPRESSION OF LATE SV-40 FACTOR - Inhibitors of Late SV-40 Factor (LSF) are used to treat cancers such as hepatocellular carcinoma (HCC). In particular, small molecule chemical LSF inhibitors are employed. In addition, the activity and/or pattern of expression of LSF may is used to diagnose cancer, to characterize the cancer (e.g. stage, grade, prognosis, etc.) and also to develop suitable protocols for cancer treatment. | 2013-01-31 |
20130028900 | METHODS AND COMPOSITIONS FOR THE GENERATION AND USE OF CONFORMATION-SPECIFIC ANTIBODIES - The present invention features methods and compositions for the generation and use of conformation-specific anti-bodies or fragments thereof. | 2013-01-31 |
20130028901 | NOVEL RECEPTOR TREM (TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS) AND USES THEREOF - Novel activating receptors of the Ig super-family expressed on human myeloid cells, called TREM(s) (triggering receptor expressed on myeloid cells) are provided. Specifically, two (2) members of TREMs, TREM-1 and TREM-2 are disclosed. TREM-1 is a transmembrane glycoprotein expressed selectively on blood neutrophils and a subset of monocytes but not on lymphocytes and other cell types and is upregulated by bacterial and fungal products. Use of TREM-1 in treatment and diagnosis of various inflammatory diseases is also provided. TREM-2 is also a transmembrane glycoprotein expressed selectively on mast cells and peripheral dendritic cells (DCs) but not on granulocytes or monocytes. DC stimulation via TREM-2 leads to DC maturation and resistance to apoptosis, and induces strong upregulation of CCR7 and subsequent chemotaxis toward macrophage inflammatory protein 3-β. TREM-2 has utility in modulating host immune responses in various immune disorders, including autoimmune diseases and allergic disorders. | 2013-01-31 |
20130028902 | OSTEOCALCIN AS A TREATMENT FOR MALE REPRODUCTIVE DISORDERS - Methods and compositions for treating, preventing, or diagnosing disorders related to reproduction in male mammals, preferably humans, are provided. The methods generally involve modulation of the OST-PTP signaling pathway or the PTP-IB signaling pathway involving gamma-carboxylase and osteocalcin. Disorders amenable to treatment by the methods include, but are not limited to, male infertility, low sperm count, impaired sperm motility, impaired sperm viability, low testosterone levels, reduced libido, erectile dysfunction, underdevelopment of testes, and excess apoptosis in testes. | 2013-01-31 |
20130028903 | PURIFIED ANTIBODY COMPOSITION - The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained. | 2013-01-31 |
20130028904 | HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF - The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting mesothelin, as well as methods for treating cancers, such as mesotheliomas, pancreatic cancers and ovarian cancers, using an anti-mesothelin antibody of this disclosure. | 2013-01-31 |
20130028905 | HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF - The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting mesothelin, as well as methods for treating cancers, such as mesotheliomas, pancreatic cancers and ovarian cancers, using an anti-mesothelin antibody of this disclosure. | 2013-01-31 |
20130028906 | HUMAN ANTIBODIES THAT BIND MESOTHELIN, AND USES THEREOF - The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting mesothelin, as well as methods for treating cancers, such as mesotheliomas, pancreatic cancers and ovarian cancers, using an anti-mesothelin antibody of this disclosure. | 2013-01-31 |
20130028907 | Stable Antibody Containing Compositions - The invention relates to stable and low viscous (<50 cP) protein containing compositions, in particular, but not exclusively stable antibody containing compositions and to the use of said stable proteins in therapy, in particular for the subcutaneous delivery of said stable protein. | 2013-01-31 |
20130028908 | MONOCLONAL ANTIBODIES DIRECTED AGAINST HIV p17 PROTEIN - Anti-HIV p17 monoclonal antibodies are described, which are capable of neutralizing the binding between multiple HIV-1 p17 protein variants and the p17R receptor are provided. Pharmaceutical compositions and methods of treatment utilizing these antibodies are also provided. | 2013-01-31 |
20130028909 | Depletion of Teratoma-Forming Pluripotent Stem Cells - Compositions and methods are provided for depletion of pluripotent cells. In one embodiment of the invention, methods are provided for depletion of pluripotent cells from a mixed population of differentiated cells and stem cells, to provide a population of cells substantially free of pluripotent stem cells. Monoclonal antibodies useful in depletion and in identification of pluripotent stem cells are also provided. | 2013-01-31 |
20130028910 | HMG1 ANTIBODY FOR TREATING INFLAMMATORY CONDITIONS - There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method for monitoring the severity or potential lethality of sepsis or septic shock, comprising measuring the serum concentration of HMG1 in a patient exhibiting or at risk of exhibiting sepsis or septic shock symptoms. Lastly, there is disclosed a phamaceutical composition and method for effecting weight loss or treating obesity, comprising administering an effective amount of HMG1 or a therapeutically active HMG1 fragment. | 2013-01-31 |
20130028911 | VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS - The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterized by undesirable or excessive neovascularization. | 2013-01-31 |
20130028912 | TWEAK/FN14 SYSTEM REGULATES SKELETAL MUSCLE ATROPHY AND REGENERATION - The invention provides methods for preventing loss and augmenting regeneration of skeletal muscle by decreasing the activity of the TWEAK/Fn14 system. | 2013-01-31 |
20130028913 | ANTIBODY THAT BINDS TO H-1 PARVOVIRUS - Described is an antibody or an antigen binding fragment thereof specifically binding to a full or empty H-1 parvovirus capsid. Such an antibody is useful for various diagnostic and therapeutic methods, e.g., for the detection/therapy of an H-1 parvovirus infection during pregnancy since parvovirus affects about 1 in 400 pregnancies and may cause fetal loss or fetal hydrops. | 2013-01-31 |
20130028914 | Antibodies that Bind Tau Oligomers - Embodiments of the invention are directed to compositions and methods related to Tau oligomers and Tau oligomer specific antibodies. | 2013-01-31 |
20130028915 | DENDRITIC CELL (DC)-VACCINE THERAPY FOR PANCREATIC CANCER - Compositions and methods for eliciting therapeutic immunity and improving clinical outcomes in patients with pancreatic cancer are disclosed herein. The present invention describes a dendritic cell (DC)-vaccine comprising DCs pulsed with peptides derived from pancreatic cancer antigens for the therapy against pancreatic cancer. The vaccine described herein is safe, and leads to expansion of cancer specific T cells in patients with pancreatic cancer. | 2013-01-31 |
20130028916 | ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS - The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus. | 2013-01-31 |